Human MIP2 ELISA Kit (CXCL2)

Product details

Human MIP2 ELISA Kit (CXCL2) ab184862 is a rapid single-wash 90-min Sandwich ELISA to measure Human MIP2 (CXCL2)in cell culture supernatant, plasma, serum. This SimpleStep sensitivity is 1 pg/mL.

How the assay works

Human MIP2 (CXCL2)SimpleStep ELISA^®employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our SimpleStep ELISA^® plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. See the SimpleStep ELISA^® protocol summary in the image section for further details.

Assay Specificity

Our SimpleStep ELISA^® kits use recombinant monoclonal antibodies rigorously validated to ensure the highest level of consistency and reproducibility, improved sensitivity and specificity and ease of scalability and security of supply.
Please refer to our protocol booklet for more details.

Human MIP2 ELISA Kit (CXCL2) ab184862 protocol summary

1. Mix: add samples/standards to the wells together with the capture and detector antibody cocktail. Incubate 1 hr at room temperature
2. Wash
3. Add TMB development solution - incubate for 10 min
4. Add Stop solution
5. Read the results on a plate reader at 450 nm

Macrophage inflammatory protein 2 (MIP2) otherwise known as CXCL2 GRO-beta| or Hematopoietic synergistic factor is a 7.9 kDa heparin-binding chemokine that has potent effects in the response to inflammation and induction of peripheral tolerance. MIP2 shares 70% sequence similarity with mouse and rat MIP2. It is secreted by activated monocytes neutrophils and inflamed mucosal epithelial cells in response to inflammatory stimuli such as IL-1β. MIP2 recruits granulocytic neutrophils and macrophages at sights of inflammation| and causes degranulation of these effector cells at the inflammatory site. It has also been hypothesized that MIP2 acts to synergize the effects of Granulocyte macrophage colony-stimulating factor (GM-CSF) and Macrophage colony-stimulating factor (M-CSF) leading to a larger recruitment of neutrophils and macrophages at the site of inflammation. Research has also suggested that MIP2 is involved in tolerogenic pathways as a lack of the MIP2 receptors CXCR1 and CXCR2 are associated with peripheral tolerance. Clinically. MIP2 is being used as a bone marrow transplant regimen to mobilize peripheral blood hematopoietic stem cells (PBSCs). Mobilization by MIP2 therapy in combination with G-CSF has been associated with faster immune cell reconstitution after transplantation.